Nasdaq Biotechnology Ishares ETF (IBB)
$143.22 4.27 (3.07%)
16:35 EST IBB Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 12.45B
PE Ratio -
Volume (Avg. Vol.) 2.27M
Day's Range 139.63 - 143.37
52-Week Range 92.15 - 146.53
Dividend & Yield 0.31 (0.22%)
IBB Stock Predictions, Articles, and Nasdaq Biotechnology Ishares ETF News
- From InvestorPlace
- From the Web
If you’re interested in high-growth biotech stocks with superior fundamentals, here are which ones to consider, and which ones to skip.
The novel coronavirus is weighing on the market, but these four biotech stocks can survive. Here's what you need to know to profit now.
This company is riding a powerful trend in the future of healthcare. Plus, it offers high growth, a huge potential market and a path to profitability.
Here are five tech ETFs to buy if you believe that global technology stocks will continue to enjoy their solid runs in the coming quarters.
Biotech stocks are winners this year, but there's still room to buy in for profit taking. ETFs such as IBB, XBI and XLV will continue to win.
Consensus is that the experts will find a vaccine to Covid-19 soon, so the biotech stocks have rallied hard. Buying them now carries risk.
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.
The buyers are in charge of the healthcare stocks this year. And judging from their charts, these stocks and ETFs in particular offer great opportunities.
By Ian Cooper
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.
The fourth quarter has been a different story. IBB, the largest biotech ETF by assets, is up 16.65% since Oct. 1, pushing its year-to-date gain to 26.57% as of Dec. 20. That after months of investors pulling money from actively managed biotech funds, but that situation is starting to correct as well as data out this month indicate investors are warming to biotech assets again.
Our research and analysis have identified another name in biotech stocks with big potential in 2020.
There's a catalyst on the horizon that could send biotech stocks soaring into the stratosphere.
By Ken Trester
This morning, I'm recommending a bullish call option on Aimmune Therapeutics, Inc. (NASDAQ:AIMT), the biopharmaceutical company.
Bitcoin, Biotech, Micron and Starbucks were our top stock trades to watch. Here's how the charts are setting up going into Friday.
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
The healthcare sector has been the worst performing on the S&P 500 in 2019, but these biotech ETFs are still worth a look.
Investors turned sour on BMY stock after the Celgene buyout. Will a solid Q2 earnings report change the sentiment for the better?